BD (NYSE:BDX) today shared the results from a preliminary study investigating the impact of deep cold storage on glass prefillable syringes.
Franklin Lakes, N.J.-based BD’s study evaluated deep cold storage (-20°C and -40°C) as traditional vaccine formulations are commonly stored up to about 2°C to 8°C, while mRNA vaccine formulations (the type of COVID-19 vaccine made by both Pfizer and Moderna), among other new ones, require much colder storage for over a long period of time to ensure drug-product shelf-life and potency.
Get the full story at our sister site, Drug Delivery Business News.